Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
CADTH Optimal Use reports, now renamed to Health Technology Review, are intended to encourage ideal prescribing, purchasing, and use of drugs or other health technologies by health care providers, policy-makers, and consumers. Generally, these are drugs or health technologies that have been available in the marketplace for some time. An Optimal Use project results in a series of documents — typically clinical and economic review reports as well as a recommendations report. CADTH Optimal Use projects are carried out in collaboration with a committee or panel comprising subject‐matter experts, public representatives, and other stakeholders from across Canada.
The Canadian Agency for Drugs and Technologies in Health (CADTH) is an independent, not-for-profit producer and broker of health technology assessments. Health care decision-makers rely on our work to make evidence-informed policy and practice decisions about drugs and other health technologies.
CADTH Optimal Use Reports was renamed to Health Technology Review on on Oct. 29, 2021, with volume 9.3c.
Contents
2020
- Internet-Delivered Cognitive Behavioural Therapy for Post-Traumatic Stress Disorder: RecommendationsOttawa (ON): Canadian Agency for Drugs and Technologies in Health; January 2020.
2019
- Axicabtagene Ciloleucel for Diffuse Large B-Cell Lymphoma: Economic Review ReportOttawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2019.
- Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Clinical ReportOttawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2019.
- Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Ethics and Implementation ReportOttawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2019.
- Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Health Technology Assessment Introduction and Clinical Review ProtocolOttawa (ON): Canadian Agency for Drugs and Technologies in Health; May 2019.
- Axicabtagene Ciloleucel for Large B-cell Lymphoma: Implementation and Ethics Project ProtocolOttawa (ON): Canadian Agency for Drugs and Technologies in Health; May 2019.
- Axicabtagene Ciloleucel for Large B-Cell Lymphoma: RecommendationsOttawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2019.
- Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended DurationGeorge A. Wells, Jesse Elliott, Shannon Kelly, Zemin Bai, Michel Boucher, Becky Skidmore, Derek So, Suzanne Laplante, and Karen Lee.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2019.
- Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration — RecommendationsOttawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2019.
- HPV Testing for Primary Cervical Cancer Screening: A Health Technology AssessmentClinical Review authors: Dr. Yi-Sheng Chao, Michelle Clark, Elizabeth Carson, Dr. Laura Weeks, Kristen Moulton, Dr. Susan McFaul, and Dr. C.M McLauchlin. Economic Evaluation author: Dr. Bernice Tsoi; Patients’ Perspectives and Experiences Review authors: Umair Majid, Sujane Kandasamy, Neha Arora, and Dr. Meredith Vanstone. Ethical Issues Analysis authors: Dr. Lynette Reid and Timothy Krahn. Implementation Issues Analysis author: Kasia Kaluzny; Research Information Specialist authors: Kelly Farrah and Caitlyn Ford.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2019.
- HPV Testing for Primary Cervical Cancer Screening: Recommendations ReportOttawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2019.
- Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: Patients’ Perspectives and Experiences, Implementation, and Ethical IssuesOttawa (ON): Canadian Agency for Drugs and Technologies in Health; February 2019.
- Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: RecommendationsOttawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2019.
- Internet-Delivered Cognitive Behavioural Therapy for Post-Traumatic Stress Disorder: A Health Technology AssessmentClinical review authors: Calvin Young and Dr. Alison Sinclair. Economic evaluation authors: Cody Black; Perspectives and experiences review authors: Elijah Herington; Implementation issues analysis author: Elijah Herington; Ethics analysis author: Dr. Maxwell Smith; Research information specialist authors: Carolyn Spry and Kaitryn Campbell. Program development officer: Bert Dolcine.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; December 2019.
- Internet-Delivered Cognitive Behavioural Therapy for Post-Traumatic Stress Disorder: A Health Technology Assessment — Project ProtocolOttawa (ON): Canadian Agency for Drugs and Technologies in Health; July 2019.
- Optimal Use of Minimally Invasive Glaucoma Surgery: A Health Technology AssessmentClinical Review Authors: Dr. Veronica Poitras, Charlotte Wells, and Dr. Cindy Hutnik. Economic Evaluation Authors: Dr. Scott Klarenback, Helen So, and Dr. Bernice Tsoi. Patients’ Perspectives and Experiences Review Authors: Andrea Smith and Elijah Herington. Ethical Issues Analysis Author: Natalie Brender; Implementation Issues Analysis author: Charlotte Wells; Research Information Specialist authors: Caitlyn Ford and Melissa Severn.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; January 2019.
- Optimal Use of Minimally Invasive Glaucoma Surgery: RecommendationsOttawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2019.
2018
- Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration — Project ProtocolOttawa (ON): Canadian Agency for Drugs and Technologies in Health; February 2018.
- Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment — Project ProtocolOttawa (ON): Canadian Agency for Drugs and Technologies in Health; June 2018.
- Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology AssessmentClinical Authors: Alison Sinclair, Kwakye Peprah, Teo Quay, Matthew McInnis, Eddy Lang, Melissa Severn, Sohail Mulla, and Laura Weeks. Bernice Tsoi, Economic Author; Patient Perspectives and Experiences Authors: Elijah Herrington and Myuri Manogaran. Sarah Garland, Implementation Author; Angel Petropaganos, Ethics Author; Environmental Authors: Kwakye Peprah and Julie Polisena.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; January 2018.
- Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: RecommendationsOttawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2018.
- Optimal Use of Minimally Invasive Glaucoma Surgery: A Health Technology Assessment — Project ProtocolOttawa (ON): Canadian Agency for Drugs and Technologies in Health; January 2018.
- Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma — Project Protocol, Clinical SectionOttawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2018.
- Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma — Project Protocol, Implementation and Ethics SectionOttawa (ON): Canadian Agency for Drugs and Technologies in Health; September 2018.
2017
- Current Practice Analysis: Interventions for Insomnia DisorderJanet Crain, Michael Raj, Sarah Garland, Sarah Jones, and Bechara Farah.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; June 2017.
- Dialysis Modalities for the Treatment of End-Stage Kidney Disease: A Health Technology AssessmentClinical authors: Dr. Alison Sinclair, Karen Cimon, Mirhad Loncar, Dr. Manish Sood, Dr. Paul Komenda, and Melissa Severn. Economic authors: Dr. Scott Klarenbach, Dr. Helen So, Dr. Bernice Tsoi, Dr. Robert Quinn, Dr. Robert Pauly, Dr. Marcello Tonelli, and Dr. Braden Manns. Patient preferences and experiences authors: Tamara Rader and Kristen Moulton. Implementation authors: Kristen Moulton, Eftyhia Helis, and Janet Crain. Ethics author: Dr. Daryl Pullman.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2017.
- Dialysis Modalities for the Treatment of End-Stage Kidney Disease: RecommendationsOttawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2017.
- HPV Testing for Primary Cervical Cancer Screening — Project ProtocolOttawa (ON): Canadian Agency for Drugs and Technologies in Health; May 2017.
- Interventions for the Treatment of Obstructive Sleep Apnea in Adults: A Health Technology AssessmentJoanne Kim, Khai Tran, Kelsey Seal, Almeida Fernanda, Ross Glenda, Roch Messier, Major, Bernice Tsoi, Sarah Garland, Tamara Rader, Katherine Duthie, Ken Bond, Janice Mann, Kelsey Seal, and David Kaunelis.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2017.
- Interventions for the Treatment of Obstructive Sleep Apnea in Adults: RecommendationsOttawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2017.
2016
- Addendum to Interventions for the Treatment of Obstructive Sleep Apnea in Adults: A Health Technology Assessment – Project ProtocolKhai Tran, Joanne Kim, Bernice Tsoi, Tamara Rader, Sarah Garland, Katherine Duthie, Ken Bond, Kelsey Seal, David Kaunelis, Dr. Fernanda Almeida, Lt. Col. Glenda Ross, and Major Roch Messier.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; June 2016.
- Dialysis Modalities for the Treatment of End-Stage Kidney Disease: A Health Technology Assessment — Project ProtocolOttawa (ON): Canadian Agency for Drugs and Technologies in Health; November 3, 2016.
- DNA Mismatch Repair Deficiency Tumour Testing for Patients With Colorectal Cancer: A Health Technology AssessmentClinical authors: Nazila Assasi, Gordon Blackhouse, Kaitryn Campbell, Katherine Gaebel, Robert Hopkins, Jathishinie Jegathisawaran, Alison Sinclair, Kelsey Seal, Chris Kamel, and Mitchell Levine. Economic authors: Gordon Blackhouse, Bernice Tsoi, Kaitryn Campbell, and Jathishinie Jegathisawaran. Patient Preferences and Experiences authors: Laura Weeks, Sarah Garland, Kristen Moulton, and David Kaunelis.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2016.
- DNA Mismatch Repair Deficiency Tumour Testing for Patients With Colorectal Cancer: Ethical IssuesKatherine Duthie, Ken Bond, and David Kaunelis.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2016.
- DNA Mismatch Repair Deficiency Tumour Testing for Patients With Colorectal Cancer: RecommendationsOttawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2016.
- Interventions for the Treatment of Obstructive Sleep Apnea in Adults: A Health Technology Assessment – Project ProtocolKhai Tran, Joanne Kim, Bernice Tsoi, Tamara Rader, Sarah Garland, Katherine Duthie, Ken Bond, Kelsey Seal, Dr. Fernanda Almeida, Lt. Col. Glenda Ross, and Major Roch Messier.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; April 2016.
- Monitoring for Atrial Fibrillation in Discharged Stroke and Transient Ischemic Attack Patients: A Clinical and Cost-Effectiveness Analysis and Review of Patient PreferencesGino De Angelis, Karen Cimon, Alison Sinclair, Kelly Farrah, Dr John Cairns, and Dr Adrian Baranchuk. Lauren E Cipriano and A Omar Akhtar. Laura Weeks, Tamara Rader, and Sarah Garland.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2016.
- Monitoring for Atrial Fibrillation in Discharged Stroke and Transient Ischemic Attack Patients: RecommendationsGino De Angelis, Karen Cimon, Alison Sinclair, Kelly Farrah, Dr. John Cairns, and Dr. Adrian Baranchuk. Lauren E. Cipriano and A. Omar Akhtar. Laura Weeks, Tamara Rader, and Sarah Garland.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2016.
- Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment — Project ProtocolOttawa (ON): Canadian Agency for Drugs and Technologies in Health; September 29, 2016.
- Point-of-Care Troponin Testing in Patients With Symptoms Suggestive of Acute Coronary Syndrome: A Health Technology AssessmentChuong Ho, Karen Cimon, Laura Weeks, Monika Mierzwinski-Urban, and Lesley Dunfield. Lesley Soril, Fiona Clement, and Mohammed Jabr.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2016.
- Point-of-Care Troponin Testing in Patients With Symptoms Suggestive of Acute Coronary Syndrome: RecommendationsChuong Ho, Karen Cimon, Laura Weeks, Monika Mierzwinski-Urban, and Lesley Dunfield. Lesley Soril, Fiona Clement, and Mohammed Jabr.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2016.
2015
- Effectiveness of Factor V Leiden and Prothrombin Mutation Testing in Patients Presenting With a First Unprovoked Venous Thromboembolic Episode: A Systematic Review and Economic AnalysisOttawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2015.
- Guidance on the Use of Factor V Leiden and Prothrombin Mutation Testing in Patients With a First Unprovoked Thromboembolic EpisodeOttawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2015.
- Mismatch Repair Deficiency Testing for Patients with Colorectal Cancer: A Clinical and Cost-Effectiveness EvaluationNazila Assasi, Gord Blackhouse, Kaitryn Campbell, Laura Weeks, and Mitchell Levine.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; September 2015.
- Monitoring for Atrial Fibrillation in Discharged Stroke and Transient Ischemic Attack Patients: A Clinical and Cost-Effectiveness Analysis and Review of Patient PreferencesGino De Angelis, Karen Cimon, Lauren Cipriano, Kelly Farrah, Sarah Garland, Dr John Cairns, and Dr Adrian Baranchuk.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; September 2015.
- Point-of-Care Cardiac Troponin Testing in Patients With Symptoms Suggestive of Acute Coronary Syndrome – Project ProtocolChuong Ho, (Research Officer/Project Lead/Co-Author), Karen Cimon, (Research Assistant/Co-Author), Mohammed Jabr, (Health Economist/Co-Author), Monika Mierzwinski-Urban, (Information Specialist/Co-Author), Fiona Clement, (Health Economist/Co-Author), Lesley Soril, (Research Analyst/Co-Author), Lesley Dunfield, (Director, HTA), Laura Weeks, (Scientific Advisor), and Pat Reynard, (Project Manager).Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; June 2015.
2014
- Guidance on the Use of Point-of-Care Testing of International Normalized Ratio for Patients on Oral Anticoagulant TherapyOttawa (ON): Canadian Agency for Drugs and Technologies in Health; July 2014.
- Point-of-Care Testing of International Normalized Ratio for Patients on Oral Anticoagulant Therapy: Systematic Review and Economic AnalysisOttawa (ON): Canadian Agency for Drugs and Technologies in Health; July 2014.
2013
- Combination Use of Insulin and Incretins in Type 2 DiabetesOttawa (ON): Canadian Agency for Drugs and Technologies in Health; July 2013.
- High-Sensitivity Cardiac Troponin for the Rapid Diagnosis of Acute Coronary Syndrome in the Emergency Department: A Clinical and Cost-Effectiveness EvaluationOttawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2013.
- Optimal Use Recommendations for Second- and Third-Line Therapy for Patients With Type 2 DiabetesOttawa (ON): Canadian Agency for Drugs and Technologies in Health; July 2013.
- Point-of-Care Testing of International Normalized Ratio for Patients on Oral Anticoagulant Therapy – Project ProtocolOttawa (ON): Canadian Agency for Drugs and Technologies in Health; July 2013.
- Recommendations for the Use of Troponin Assays for Rapid Diagnosis of Acute Coronary Syndrome in the Emergency DepartmentOttawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2013.
- Second-Line Pharmacotherapy for Type 2 Diabetes — UpdateOttawa (ON): Canadian Agency for Drugs and Technologies in Health; July 2013.
- Third-Line Pharmacotherapy for Type 2 Diabetes — UpdateOttawa (ON): Canadian Agency for Drugs and Technologies in Health; July 2013.
2012
- Current Utilization of Antipsychotic Agents for Schizophrenia: Combination and High-Dose TherapiesOttawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2012.
- High-Sensitivity Cardiac Troponin for the Rapid Diagnosis of Acute Coronary Syndrome in the Emergency Department: A Clinical and Cost-Effectiveness Evaluation: ProtocolOttawa (ON): Canadian Agency for Drugs and Technologies in Health; November 2012.
- Large Volumetric Infusion Pumps: Inventory Management and Usability SurveysOttawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2012.
- Optimal Use of Atypical Antipsychotics for Schizophrenia: Combination Therapy, High Doses, and Clozapine — Current Practice StudyOttawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2012.
- Optimizing Health System Use of Medical Isotopes and Other Imaging ModalitiesMichelle Mujoomdar, Erin Russell, François Dionne, Kristen Moulton, Christine Murray, Sarah McGill, and Kimberlee Lambe.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2012.
- Second- and Third-Line Pharmacotherapy for Type 2 Diabetes — Update of CADTH 2010 Reviews — Project ProtocolOttawa (ON): Canadian Agency for Drugs and Technologies in Health; November 2012.
- Warfarin Management in Patients with Atrial Fibrillation — Current Practice StudyOttawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2012.
2011
- 1.5 Tesla Magnetic Resonance Imaging Scanners Compared with 3.0 Tesla Magnetic Resonance Imaging Scanners: Systematic Review of Clinical Effectiveness: Pilot ProjectRonald Wood, Ken Bassett, Vicki Foerster, Carolyn Spry, and Leonard Tong.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; May 2011.
- Addendum to a Systematic Review of Clinical, Laboratory and Safety Outcomes Associated with Use of Octaplas in Multiple Clinical Indications: Pilot ProjectMadzouka Kokolo, Alan Tinmouth, and Dean Fergusson.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; May 2011.
- Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses — Project ProtocolOttawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2011.
- Ethical Assessment: Open versus Restricted Access and Optimal Use of Solvent/ Detergent-Treated Human Plasma (Octaplas): Pilot ProjectMichael Kekewich and Thomas Foreman.Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; May 2011.
- Guidance on 1.5 Tesla Magnetic Resonance Imaging Scanners Compared with 3.0 Tesla Magnetic Resonance Imaging Scanners: Pilot ProjectOttawa (ON): Canadian Agency for Drugs and Technologies in Health; May 2011.
- Optimal Therapy Recommendation for the Use of Solvent/Detergent-Treated Human Plasma: Pilot ProjectOttawa (ON): Canadian Agency for Drugs and Technologies in Health; May 2011.
- Optimal Use Recommendations for Atypical Antipsychotics: Combination and High-Dose Treatment Strategies in Adolescents and Adults with SchizophreniaOttawa (ON): Canadian Agency for Drugs and Technologies in Health; December 2011.
- Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical EvidenceOttawa (ON): Canadian Agency for Drugs and Technologies in Health; November 2011.
- Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: Review of Canadian Economic StudiesOttawa (ON): Canadian Agency for Drugs and Technologies in Health; November 2011.
- Recommendations for Optimal Warfarin Management for Prevention of Thromboembolic Events in Patients with Atrial FibrillationOttawa (ON): Canadian Agency for Drugs and Technologies in Health; November 2011.
- A Systematic Review of Combination and High-Dose Atypical Antipsychotic Therapy in Patients with SchizophreniaOttawa (ON): Canadian Agency for Drugs and Technologies in Health; December 2011.
- Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.[Curr Oncol. 2022]Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.Ball G, Levine MAH, Thabane L, Tarride JE. Curr Oncol. 2022 Oct 13; 29(10):7624-7636. Epub 2022 Oct 13.
- Patients' perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH Common Drug Review.[Res Involv Engagem. 2016]Patients' perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH Common Drug Review.Berglas S, Jutai L, MacKean G, Weeks L. Res Involv Engagem. 2016; 2:21. Epub 2016 Jun 7.
- The future of Cochrane Neonatal.[Early Hum Dev. 2020]The future of Cochrane Neonatal.Soll RF, Ovelman C, McGuire W. Early Hum Dev. 2020 Nov; 150:105191. Epub 2020 Sep 12.
- Review Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021.[Curr Oncol. 2022]Review Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021.Lau C, Dranitsaris G. Curr Oncol. 2022 Oct 26; 29(11):8031-8042. Epub 2022 Oct 26.
- Review Second- and Third-Line Pharmacotherapy for Type 2 Diabetes — Update of CADTH 2010 Reviews — Project Protocol[ 2012]Review Second- and Third-Line Pharmacotherapy for Type 2 Diabetes — Update of CADTH 2010 Reviews — Project Protocol. 2012 Nov
- CADTH Optimal Use ReportsCADTH Optimal Use Reports
- REFERENCES - Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A...REFERENCES - Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment — Project Protocol
- ECONOMIC REVIEW - Optimal Strategies for the Diagnosis of Acute Pulmonary Emboli...ECONOMIC REVIEW - Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment — Project Protocol
- Optimal Strategies to Diagnose Acute Pulmonary Embolism - CADTH Report / Project...Optimal Strategies to Diagnose Acute Pulmonary Embolism - CADTH Report / Project in Briefs
Your browsing activity is empty.
Activity recording is turned off.
See more...